Hy2Care® BV Secures €4.5 Million to Accelerate Next-Gen Orthopedic Innovation

Hy2Care® BV is thrilled to announce that it has successfully raised 4,500,000 euros in its latest funding round, marking a significant milestone in its journey from university spin-off to innovative biotech leader. As a spin-off of the renowned MIRA Institute at the University Twente—the Netherlands, one of the world’s leading institutions in biomedical and chemical engineering—Hy2Care® has been dedicated to advancing groundbreaking technologies since its inception in 2007. To date, the company has attracted over 4 million euros in investments to develop a unique platform technology that promises to revolutionize orthopedic healthcare. With three patents already filed in Europe and the United States, and further intellectual property filings underway, Hy2Care® is strategically positioning itself at the forefront of medical innovation. The recently secured funding will primarily be used to accelerate product development and refinement, with a crucial focus on scaling up prototyping efforts and advancing further into pre-clinical and clinical testing phases. Initial milestones, including successful product prototyping and first animal testing, have paved the way for a promising future, while face-to-face interviews with key opinion leaders and extensive market studies have confirmed the product’s high potential, thanks to strong interest expressed by internationally acclaimed orthopedic surgeons. This investment will enhance Hy2Care®’s capability to bring their novel solutions from the lab to the operating room, ultimately improving patient outcomes and addressing unmet needs in orthopedic care. The company’s ambitious vision, combined with dedicated research and strategic funding, sets a robust foundation for future growth and innovation in the biomedical field.